News & Updates

Finerenone confers consistent cardiorenal benefits in patients with CKD and T2D regardless of SGLT-2i use
Finerenone confers consistent cardiorenal benefits in patients with CKD and T2D regardless of SGLT-2i use
17 Nov 2021 byAudrey Abella

In patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) who were receiving the novel nonsteroidal MRA* finerenone, use of SGLT-2is** at baseline did not influence treatment outcomes, according to a subgroup analysis of the FIDELITY*** trial presented at ASN 2021.

Finerenone confers consistent cardiorenal benefits in patients with CKD and T2D regardless of SGLT-2i use
17 Nov 2021
TAF rivals TDF for CHB suppression after orthotopic liver transplantation
TAF rivals TDF for CHB suppression after orthotopic liver transplantation
17 Nov 2021
Tenofovir alafenamide safe to use in breastfeeding mothers with CHB
Tenofovir alafenamide safe to use in breastfeeding mothers with CHB
16 Nov 2021